Off Patent
July 2026

Spiriva

tiotropium bromide

Boehringer Ingelheim Pharmaceuticals Inc

Powder (inhalation) · NDA 021395

Last listed protection ended
July 19, 2026

The FDA listed 1 patent for Spiriva, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities

  1. Ended
    Patent 8,022,082
    Claims the drug product and a use (U-1186)
  2. Ended
    Patent 8,022,082
    Pediatric extension: six more months